News Archive

Next-Generation Liquid Embolic, NeoCast™, Successfully Occludes Distal Middle Meningeal Artery
Branches of Chronic Subdural Hematoma Patients in Initial Cohort of First-In-Human Study

First Patient Enrolled in Trial to Evaluate Safety and Feasibility of Innovative Embolic Agent in Expanded Patient Population Utilizing Middle Meningeal Artery Embolization (MMAe)

Data show NeoCast™ met primary endpoints and enabled significant distal penetration of hypervascular brain tumors

NeoCast occluded approximately five times more vessel branches compared to the market-leading liquid embolic agent in swine kidneys

Interview with Upma Sharma, President and CEO of Arsenal Medical

Successful deployment of Arsenal's investigational first-in-class, embolic biomaterial for neurovascular conditions

First-in-class, solvent-free biomaterial achieves occlusion of small blood vessels with minimal inflammation

For the next few months, King and his colleagues are reaching out to the community to share information about the clinical trial. “Part of this process is establishing a dialogue with the community and vetting what we think we have already figured out,” King says.

The FDA has approved the use of a potentially lifesaving foam on patients in a clinical trial at a Boston hospital.

Arsenal Medical has developed a foam system, called ResQFoam™, is designed to control acute hemorrhage. The way ResQFoam works is by injecting two liquid polymers, which together combine to create a foam. This foam quickly expands though actively flowing blood to compresses the injury and control bleeding. Upon undergoing surgery, the material is removed by the surgeon.